In this Axios column, Drew Altman wades in to the Medicare for All discussion focusing on the pros and cons of a critical but under-discussed feature of the proposals-they have no cost sharing.
Category: Medicare
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Ask Us Anything!
From Medicare dental coverage to drug prices to fetal tissue research, the panelists answer listeners’ questions. Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner.
En Route To Congress, California Democrats Hit Wall On ‘Medicare-For-All’
California’s incoming congressional delegation will be the largest in the U.S. House of Representatives to support progressive health care policies such as “Medicare-for-all.” But the political reality of a Republican Senate and president means that they will need to pursue ideas that “aren’t pie in the sky.”
Podcast: KHN’s ‘What The Health?’ More On That Texas Lawsuit, And The Best And Worst Health Policy Stories Of The Year
The fallout continues from that Texas court decision that ruled Congress’ 2017 elimination of the tax penalty for failing to have insurance rendered the entire Affordable Care Act unconstitutional. Meanwhile, enrollment for 2019 at healthcare.gov was down, but far less than many predicted. KHN’s Julie Rovner, along with panelists Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of the Washington Examiner, discuss this, plus the best, most overhyped and nerdiest stories of 2018. Also, Rovner interviews GOP strategist and pollster Frank Luntz.
5 Ways Nixing The Affordable Care Act Could Upend The Entire Health System
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
Feds Order More Weekend Inspections Of Nursing Homes To Catch Understaffing
Medicare instructs inspectors to look for staffing inadequacies in homes that report suspiciously low numbers of registered nurses and weekend workers.
Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”
Chronically Ill, Traumatically Billed: The $123,000 Medicine For MS
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
